Sareum’s Lead Asset Hangs In Balance As GSK Withdraws From Oncology Pact
Following Acquisition Of Sierra
Executive Summary
The big pharma has returned the global commercial rights to Sareum’s lead program which GSK gained as part of its recently completed acquisition of Sierra Oncology, leaving Sareum scrambling for a new path forward.